Ed Arce
Stock Analyst at HC Wainwright & Co.
(3.20)
# 949
Out of 4,843 analysts
485
Total ratings
40.56%
Success rate
2.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MTVA MetaVia | Reiterates: Buy | $12 | $0.65 | +1,745.59% | 3 | Apr 16, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $7.5 | $0.59 | +1,180.30% | 27 | Apr 11, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $12.53 | +378.85% | 31 | Apr 10, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $3.03 | +147.52% | 36 | Apr 4, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $3.13 | +314.95% | 16 | Apr 2, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Neutral | n/a | $1.31 | - | 17 | Apr 2, 2025 | |
| TLPH Talphera | Reiterates: Buy | $6 | $0.49 | +1,124.49% | 6 | Apr 1, 2025 | |
| ALGS Aligos Therapeutics | Reiterates: Buy | $70 | $5.29 | +1,223.25% | 6 | Mar 31, 2025 | |
| DRRX DURECT | Reiterates: Neutral | n/a | $0.53 | - | 13 | Mar 27, 2025 | |
| ASMB Assembly Biosciences | Reiterates: Neutral | n/a | $14.01 | - | 8 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $0.39 | +2,976.92% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.35 | - | 24 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $3.55 | +801.41% | 11 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $35 | $21.75 | +60.92% | 22 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $75 | $49.65 | +51.06% | 25 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $29 → $21 | $9.84 | +113.41% | 22 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $44.42 | +62.09% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $275.26 | +47.13% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $3.67 | +49.86% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $34.03 | +179.17% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $5.91 | +204.83% | 11 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $4.51 | +188.25% | 18 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $3.36 | +48.81% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $22 | $15.02 | +46.47% | 20 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $18.11 | +165.05% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $3.11 | +141.16% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.00 | +400.00% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $7.84 | +65.82% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 → $240 | $0.63 | +38,153.11% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.15 | - | 8 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $18.95 | +31.93% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.43 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $18.22 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $26.80 | -73.88% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $29.14 | -27.93% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.98 | - | 2 | Feb 15, 2017 |
MetaVia
Apr 16, 2025
Reiterates: Buy
Price Target: $12
Current: $0.65
Upside: +1,745.59%
Unicycive Therapeutics
Apr 11, 2025
Reiterates: Buy
Price Target: $7.5
Current: $0.59
Upside: +1,180.30%
Arcturus Therapeutics Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $60
Current: $12.53
Upside: +378.85%
Akebia Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $7.5
Current: $3.03
Upside: +147.52%
Inventiva
Apr 2, 2025
Reiterates: Buy
Price Target: $13
Current: $3.13
Upside: +314.95%
Galectin Therapeutics
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.31
Upside: -
Talphera
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $0.49
Upside: +1,124.49%
Aligos Therapeutics
Mar 31, 2025
Reiterates: Buy
Price Target: $70
Current: $5.29
Upside: +1,223.25%
DURECT
Mar 27, 2025
Reiterates: Neutral
Price Target: n/a
Current: $0.53
Upside: -
Assembly Biosciences
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $14.01
Upside: -
Mar 19, 2025
Reiterates: Buy
Price Target: $12
Current: $0.39
Upside: +2,976.92%
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.35
Upside: -
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $3.55
Upside: +801.41%
Mar 10, 2025
Maintains: Buy
Price Target: $24 → $35
Current: $21.75
Upside: +60.92%
Mar 3, 2025
Maintains: Buy
Price Target: $72 → $75
Current: $49.65
Upside: +51.06%
Feb 28, 2025
Reiterates: Buy
Price Target: $29 → $21
Current: $9.84
Upside: +113.41%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $44.42
Upside: +62.09%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $275.26
Upside: +47.13%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $3.67
Upside: +49.86%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $34.03
Upside: +179.17%
Feb 11, 2025
Reiterates: Buy
Price Target: $18
Current: $5.91
Upside: +204.83%
Feb 7, 2025
Reiterates: Buy
Price Target: $13
Current: $4.51
Upside: +188.25%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $3.36
Upside: +48.81%
Jan 15, 2025
Maintains: Buy
Price Target: $18 → $22
Current: $15.02
Upside: +46.47%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $18.11
Upside: +165.05%
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $3.11
Upside: +141.16%
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $1.00
Upside: +400.00%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $7.84
Upside: +65.82%
Mar 26, 2024
Reiterates: Buy
Price Target: $12 → $240
Current: $0.63
Upside: +38,153.11%
Mar 20, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.15
Upside: -
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $18.95
Upside: +31.93%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.43
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $18.22
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $26.80
Upside: -73.88%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $29.14
Upside: -27.93%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $2.98
Upside: -